Dinesh Khanna, MD, MS, Frederick G..L. Huetwell Professor of Rheumatology and Associate Professor of Internal Medicine in the Division of Rheumatology, is the director of the University of Michigan Scleroderma Program effective July 1, 2011.
Originally from New Delhi, India, Dr. Khanna received his medical degree from the University College of Medical Sciences. He completed his postdoctoral training as an intern and resident in internal medicine at Wright State University School of Medicine in Dayton, Ohio, and a clinical and research fellowship in rheumatology and a master’s in clinical research at the University of California at Los Angeles School of Medicine. Dr. Khanna was Assistant Professor of Medicine at the David Geffen School of Medicine at UCLA. He was also the Clinical Director of UCLA’s Scleroderma Clinic.
Dr. Khanna is the author of over 200 peer-reviewed publications and book chapters. He has won numerous awards, including the 2007 Spirit of Leadership Award and the 2011 “Best Doctor of the Year” award from the Scleroderma Foundation. He is board certified in rheumatology. Dr. Khanna is currently funded by the National Institutes of Health and is particularly interested in the design of clinical trials and assessing patient reported outcomes in patients with scleroderma and leading novel international clinical trials in scleroderma. He is leading the recently funded investigator-initiated trial were recently award a $7 million investigator-initiated award from Bristol-Myers Squibb to conduct an international clinical trial in patients with diffuse systemic sclerosis. The $7 million dollar Abatacept Systemic SclErosis Trial (ASSET) evaluates abatacept (Orencia®), which is FDA approved for the treatment of rheumatoid arthritis, to reduce the symptoms of sclerosis. In addition, mechanistic work in the trial is supported by the NIH/NIAID as part of the Clinical Autoimmunity Center of Excellence grant to the University of Michigan (PI: Dr. David Fox; Project PI: Dr. Dinesh Khanna). More information on the ASSET trial can be found at www.scleroderma-asset-study.org.
Dr. Khanna is a fellow of the American College of Rheumatology. He was elected by his peers to the 2011-2013 Best Doctors in America, which recognizes the area’s top clinicians.
See a listing of Dr. Khanna’s publications on PubMed, a service of the National Library of Medicine.
back to top
Kristine Phillips, M.D., Ph.D., is an Assistant Professor at the University of Michigan School of Medicine.
Dr. Phillips joined the University of Michigan in 2005 following a faculty appointment at Harvard Medical School, Brigham and Women's Hospital. She completed medical school and residency at Johns Hopkins Hospital, and trained in Rheumatology at Brigham and Women's Hospital at Harvard Medical School.
In addition to her work with the Scleroderma Program, Dr. Phillips’ research interests include examining outcomes of patients with arthritis. She is Prinicipal Investigator and co-investigator for a number of rheumatology clinical trials at the University of Michigan.
See a listing of Dr. Phillips’ publications on PubMed, a service of the National Library of Medicine.
back to top
Elena Schiopu, M.D., is Clinical Assistant Professor in the Division of Rheumatology and active faculty in the University of Michigan Scleroderma Program. She joined the faculty in August 2005, after she finished rheumatology fellowship training at Detroit Medical Center/Wayne State University. She is board certified in both internal medicine and rheumatology.
Her interest in scleroderma started during her general medicine internship at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School in New Brunswick, NJ., where she received clinical and research training in their Scleroderma Program.
Dr. Schiopu is a member of the Board of Directors of the Scleroderma Foundation - Michigan Chapter and is a very involved presence in the education of patients.
Her roles in the University of Michigan Scleroderma Program include patient care and education of medical students and postgraduate trainees. She is active in numerous research projects focused currently on treatment strategies, measures of outcome and translational studies of potential laboratory markers of disease activity.
See a listing of Dr. Schiopu’s publications on PubMed, a service of the National Library of Medicine.
Eliza PS Tsou, Ph.D., is Research Fellow at the Division of Rheumatology at the University of Michigan. She received her PhD in Pharmaceutical Sciences from the State University of New York at Buffalo and joined UM in 2008.
Dr. Tsou’s main role is conducting scleroderma research. She has been actively involved in numerous scleroderma research projects, examining the mechanism of tissue fibrosis and vasculopathy in scleroderma. She utilizes cells isolated from skin biopsies from healthy volunteers as well as scleroderma patients and determines the key factors affecting the disease pathogenesis. Dr. Tsou is currently supported by the Arthritis Foundation.
to Faculty - Top